两种免疫抑制方案治疗IgA肾病的效果
STOP-IgAN试验二次意向治疗分析纳入162例经6个月优化支持治疗后尿蛋白>0.75 g/d的IgA肾病患者,随机分为持续支持治疗或加用免疫抑制。仅糖皮质激素单药治疗组完全临床缓解率高于支持治疗组(20% vs 6%,OR 5.31,95%CI 1.07-26.36,P=0.02),但两种免疫抑制方案均未减少GFR下降,且不良事件更常见。
要点
- 仅糖皮质激素单药治疗可提高完全临床缓解率(20% vs 6%)。
- 两种免疫抑制方案均未显著减少GFR下降≥15 ml/min/1.73m²。
- 免疫抑制治疗组严重感染、糖耐量异常和/或体重增加更常见。
核心结论
- 仅糖皮质激素单药治疗使少数GFR相对保留且持续蛋白尿的IgA肾病患者获得疾病缓解。
- 两种免疫抑制方案均未阻止GFR下降,且均与显著不良事件相关。
研究设计与样本
- STOP-IgAN试验的二次意向治疗分析,共162例经6个月优化支持治疗后尿蛋白>0.75 g/d的IgA肾病患者。
- 随机分为持续支持治疗或加用免疫抑制:GFR≥60 ml/min/1.73m²者接受6个月糖皮质激素单药治疗;GFR 30-59 ml/min/1.73m²者接受环磷酰胺3个月后序贯硫唑嘌呤联合口服泼尼松龙。
- 共同主要终点为3年试验期间完全临床缓解和GFR下降≥15 ml/min/1.73m²。
主要发现
- 糖皮质激素单药治疗组完全临床缓解11例(20%),支持治疗组3例(6%),OR 5.31(95%CI 1.07-26.36),P=0.02。
- 免疫抑制联合治疗组与支持治疗组完全临床缓解率分别为11%和4%,差异无统计学意义(P=0.30)。
- GFR下降≥15 ml/min/1.73m²终点在各组间无差异。
- 仅糖皮质激素单药治疗在12个月时短暂减少蛋白尿。
- 第一年内严重感染、糖耐量异常和/或体重增加在两种免疫抑制方案中均比支持治疗更常见。
临床怎么用
- 对于经优化支持治疗后仍持续蛋白尿且GFR相对保留的IgA肾病患者,糖皮质激素单药治疗可考虑用于诱导缓解,但需权衡感染等不良事件风险。
- 免疫抑制联合方案(环磷酰胺序贯硫唑嘌呤联合泼尼松龙)未显示阻止GFR下降的获益,且不良事件增加,不推荐常规使用。
局限性
- 本文为二次意向治疗分析,各免疫抑制亚组样本量较小。
- 完全临床缓解率差异的95%CI较宽(1.07-26.36),精确性有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The role of immunosuppression in IgA nephropathy (IgAN) is controversial. In the Supportive Versus Immunosuppressive Therapy for the Treatment of Progressive IgA Nephropathy (STOP-IgAN) Trial, 162 patients with IgAN and proteinuria >0.75 g/d after 6 months of optimized supportive care were randomized into two groups: continued supportive care or additional immunosuppression (GFR≥60 ml/min per 1.73 m2: 6-month corticosteroid monotherapy; GFR=30-59 ml/min per 1.73 m2: cyclophosphamide for 3 months followed by azathioprine plus oral prednisolone). Coprimary end points were full clinical remission and GFR loss ≥15 ml/min per 1.73 m2 during the 3-year trial phase. In this secondary intention to treat analysis, we separately analyzed data from each immunosuppression subgroup and the corresponding patients on supportive care. Full clinical remission occurred in 11 (20%) patients receiving corticosteroid monotherapy and three (6%) patients on supportive care (odds ratio, 5.31; 95% confidence interval, 1.07 to 26.36; P=0.02), but the rate did not differ between patients receiving immunosuppressive combination and controls on supportive care (11% versus 4%, respectively; P=0.30). The end point of GFR loss ≥15 ml/min per 1.73 m2 did not differ between groups. Only corticosteroid monotherapy transiently reduced proteinuria at 12 months. Severe infections, impaired glucose tolerance, and/or weight gain in the first year were more frequent with either immunosuppressive regimen than with supportive care. In conclusion, only corticosteroid monotherapy induced disease remission in a minority of patients who had IgAN with relatively well preserved GFR and persistent proteinuria. Neither immunosuppressive regimen prevented GFR loss, and both associated with substantial adverse events.
引用
- Rauen T, Fitzner C, Eitner F, et al. Effects of Two Immunosuppressive Treatment Protocols for IgA Nephropathy. J Am Soc Nephrol. 2017. PMID: 29042456. doi:10.1681/ASN.2017060713
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。